ID   AHH-1 TK+/- L3
AC   CVCL_UU62
SY   L3
DR   Wikidata; Q93323821
RX   PubMed=1793807;
RX   PubMed=2706743;
RX   PubMed=7739402;
CC   Population: Caucasian.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_UU61 ! AHH-1 TK+/-
SX   Male
AG   33Y
CA   Transformed cell line
DT   Created: 25-02-19; Last updated: 29-06-23; Version: 5
//
RX   PubMed=1793807; DOI=10.1021/tx00023a013;
RA   Crespi C.L., Gonzalez F.J., Steimel D.T., Turner T.R., Gelboin H.V.,
RA   Penman B.W., Langenbach R.;
RT   "A metabolically competent human cell line expressing five cDNAs
RT   encoding procarcinogen-activating enzymes: application to mutagenicity
RT   testing.";
RL   Chem. Res. Toxicol. 4:566-572(1991).
//
RX   PubMed=2706743; DOI=10.1093/carcin/10.5.885;
RA   Davies R.L., Crespi C.L., Rudo K., Turner T.R., Langenbach R.;
RT   "Development of a human cell line by selection and drug-metabolizing
RT   gene transfection with increased capacity to activate promutagens.";
RL   Carcinogenesis 10:885-891(1989).
//
RX   PubMed=7739402; DOI=10.1093/mutage/10.1.53;
RA   Dobo K.L., Giver C.R., Eastmond D.A., Rumbos H.S., Grosovsky A.J.;
RT   "Extensive loss of heterozygosity accounts for differential mutation
RT   rate on chromosome 17q in human lymphoblasts.";
RL   Mutagenesis 10:53-58(1995).
//